World News Blogger, Actress, Celebrity Blogger, Casting Calls, Celebrity TV and Sports News By Latrice Butts @ https://latricebutts.wordpress.com/
I have severe rheumatoid arthritis, I was in AbbVie’s Upadacitinib (ABT-494) Rheumatoid Arthritis study.
I let the study group know that I had gotten 3 blood clots but they said it wasn’t because of that medication so I kept taking it then I had 3 blood clots in the lungs and was hospitalized. And that I believed that I’ve gotten the 3 blood clots in the lungs from the study meds. Upadacitinib.
Now AbbVie’s Upadacitinib (ABT-494) is saying that they Meet All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis.
They also wanted me to sign the Research consent forms everyone know that 7 people got blood clots out of a thousand so I decided to leave the study. I knew that I was one of the participants the group that had gotten blood clots. Even thought they said that their drug didn’t cause it ” But I know it ” I’ve never in my life gotten blood clots.
So I left the study. People need to be aware that this study medication for rheumatoid arthritis is not safe two patients have died that I know of and 7 others has gotten blood clot because of this medication and I was one of the seven. This drug does not need to be approved by the FDA and people need to be aware it is not safe.
I have a copy that AbbVie wanted me to sign to continue the drug showing that at least seven people have gotten blood clots and I would not sign it at all I terminated this study.
I’m attaching portions of 2 copies of the forms below.below..
Also I notice that both of AbbVie’s forms said that the following cancers have been reported in 2 or more participants dosed with Upadacitinib breast & skin cancers & lymphomas a Type of blood cancer. So Cancer & Blood Clots..
According to researchers, the two patient deaths include one for unknown causes. A second patient in the 30 mg dose group came down with a fever and had problems with diarrhea. The subject subsequently experienced heart failure and presumed pulmonary embolism.
I started on this study medication around November 2017 when I first begin taking this drug I started to have “shortness of breath” told the Rheumatologist and the nursing team at the research center about this problems I was having with the study meds the Physician told me oh your shortness of breath isn’t common from the study meds they don’t do that.
So I kept taking them my breathing kept getting worse I kept complaining about the problem the study Rheumatologist at the research center told me to see my family doctor. So I did I went to my family doctor everything checked out ok. But I was getting worse I could just walk from room to room & I could barley breath so I decided to go to the Emergency room they also ran test and couldn’t find anything until I to them to do an X-Ray of my lungs so they did ” That’s Wen The Saw 3 Blood Clots In My Lung” and immediately put me in the hospital.
After hearing about 2 people passably dying because of this drug and I had problems with this drug since day on along with getting 3 blood clots in the lungs I can’t let this drug go to market it to dangerous.
Now their saying that: AbbVie’s Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis
AbbVie is a pharmaceutical company that discovers, develops and markets both biopharmaceuticals and small molecule drugs . It originated in 2013 as a spin-off of Abbott …
Headquarters: Lake Bluff, Illinois, United States
Number of employees: 30,000 (2016)
Revenue: $25.638 billion (2016)
Net income: $5.953 billion (2016
The Study I was on was Upadacitinib (ABT-494) is a JAK1 selective inhibitor to treat Rheumatoid Arthritis.